Mandate

Vinge has advised Santander Consumer Bank AS

March 16, 2020 Banking and Finance

Vinge has advised Santander Consumer Bank AS in connection with its acquisition of all shares in Forso Nordic AB, a subsidiary within the Ford Motor Company group.

Forso Nordic AB is a consumer credit institution who provides financial arrangements for leasing of vehicles in Scandinavia via its branches and subsidiary. The business includes to actively support sales and marketing of Ford Motor Company’s products on the Nordic market and directly or indirectly support the dealer’s sale and marketing of vehicles, spare parts and other vehicle products, by offering financing and administrative services relating thereto.

Vinge’s team consisted of Christina Kokko, Ulrich Ziche, Michaela Cronemyr, Isabelle Jengsell, Hanna Risberg, Clara Sohlberg (M&A), Emma-Stuart Beck, Caroline Krassén, Paulina Malmberg, Elin Samara (Regulatory), Nicklas Thorgerzon (GDPR/IT), Trine Osen Bergqvist, Christina Åqvist (Competition), Sofia Landolsi (Agreements), Ilze Lukins (IPR), Karolina Cohrs (Real Estate), Josefine Lanker (Banking and Finance), Hayaat Ibrahim (CSR), Lisa Ullman (Employment), Viktoria Owetz (VDR Specialist) och Bonnie Holmström (Project Assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024